Transients of Mn internal 3d5 luminescence in ZnS/Mn nanowires are strongly non-exponential. This non-exponential decay arises from an excitation transfer from the Mn ions to so-called killer centers, i.e., non-radiative defects in the nanostructures and is strongly related to the interplay of the characteristic length scales of the sample such as the spatial extensions, the distance between killer centers, and the distance between Mn ions. The transients of the Mn-related luminescence can be quantitatively described on the basis of a modified Förster model accounting for reduced dimensionality. Here, we confirm this modified Förster model by varying the number of killer centers systematically. Additional defects were introduced into the ZnS/Mn nanowire samples by irradiation with neon ions and by varying the Mn implantation or the annealing temperature. The temporal behavior of the internal Mn2+ (3d5) luminescence is recorded on a time scale covering almost four orders of magnitude. A correlation between defect concentration and decay behavior of the internal Mn2+ (3d5) luminescence is established and the energy transfer processes in the system of localized Mn ions and the killer centers within ZnS/Mn nanostructures is confirmed. If the excitation transfer between Mn ions and killer centers as well as migration effects between Mn ions are accounted for, and the correct effective dimensionality of the system is used in the model, one is able to describe the decay curves of ZnS/Mn nanostructures in the entire time window.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3211286 | PMC |
http://dx.doi.org/10.1186/1556-276X-6-228 | DOI Listing |
Sports Med Open
January 2025
Institute of Primary Care, University of Zurich, Zurich, Switzerland.
Background: Marathon training and running have many beneficial effects on human health and physical fitness; however, they also pose risks. To date, no comprehensive review regarding both the benefits and risks of marathon running on different organ systems has been published.
Main Body: The aim of this review was to provide a comprehensive review of the benefits and risks of marathon training and racing on different organ systems.
J Intern Med
January 2025
Department of Anesthesiology and Intensive Care Medicine (CCM, CVK), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background: Five fulfilled hemophagocytic lymphohistiocytosis (HLH)-2004 criteria, and the HScore are widely used and recommended by international expert consensus to diagnose secondary HLH. Both diagnostic scores have never been validated in heterogeneous patient cohorts of secondary HLH patients. We aimed to systematically optimize and validate diagnostic criteria of secondary HLH using a multicenter approach.
View Article and Find Full Text PDFFront Immunol
January 2025
Team Immunity and Cancer, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, University of Aix-Marseille UM105, Marseille, France.
Introduction: Acute myeloid leukemia (AML) is a rare haematological cancer with poor 5-years overall survival (OS) and high relapse rate. Leukemic cells are sensitive to Natural Killer (NK) cell mediated killing. However, NK cells are highly impaired in AML, which promote AML immune escape from NK cell immune surveillance.
View Article and Find Full Text PDFNIHR Open Res
January 2025
Centre for Health Services Studies, University of Kent, Canterbury, England, CT2 7NF, UK.
Background: Opioids are frequently prescribed for short-term acute pain following surgery. Used appropriately, opioids deliver extremely favourable pain relief. Used longer than 90-days, however, can result in health complications, including unintentional overdose and addiction.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
Background: A number of immunotherapeutic approaches have been developed and are entering the clinic. Bispecific antibodies (BsAbs) are one of these modalities and induce robust efficacy by endogenous T cells in several hematological malignancies. However, most of the treated patients experience only a temporary benefit.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!